Patents by Inventor Kathleen R. Whitten

Kathleen R. Whitten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Patent number: 6605721
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: August 12, 2003
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Publication number: 20030135051
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Application
    Filed: October 22, 2002
    Publication date: July 17, 2003
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Patent number: 6512135
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: January 28, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Publication number: 20020161236
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Application
    Filed: April 2, 2002
    Publication date: October 31, 2002
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 6465661
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: October 15, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Patent number: 6407285
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: June 18, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 6392067
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: May 21, 2002
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Publication number: 20020038027
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Application
    Filed: June 26, 2001
    Publication date: March 28, 2002
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 6316625
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: November 13, 2001
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Processes for making nelfinavir mesylate
    Patent number: 6303786
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: October 16, 2001
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 6117999
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: September 12, 2000
    Assignees: Agouron Phramaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Intermediates for making HIV-protease inhibitors
    Patent number: 6084107
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: July 4, 2000
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
    Patent number: 5962725
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: October 5, 1999
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
    Patent number: 5925759
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: July 20, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Intermediates for making HIV-protease inhibitors
    Patent number: 5705647
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive intermediates.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: January 6, 1998
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Srinivasan Babu, Bennett C. Borer, Travis P. Remarchuk, Robert J. Szendroi, Kathleen R. Whitten, Juliette K. Busse, Kim F. Albizati
  • Process of making alkoxy cycloalkanol esters of dihydrolysergic acid
    Patent number: 4968802
    Abstract: Alkoxycycloalkyl esters of 1-substituted-6-C.sub.1-4 straight chain alkyl (or allyl)ergoline-8.beta.-carboxylic acids, useful as 5HT receptor antagonists.
    Type: Grant
    Filed: January 10, 1990
    Date of Patent: November 6, 1990
    Assignee: Eli Lilly and Company
    Inventors: William L. Garbrecht, Gifford P. Marzoni, Kathleen R. Whitten
  • Cycloalkanol esters of dihydrolysergic acid
    Patent number: 4939258
    Abstract: Cycloalkyl or ketocycloalkyl esters of 1-substituted-6-C.sub.1-4 straight chain alkyl (or allyl)-ergoline-8.beta.-carboxylic acids, useful as 5HT receptor antagonists.
    Type: Grant
    Filed: January 10, 1990
    Date of Patent: July 3, 1990
    Assignee: Eli Lilly and Company
    Inventors: Kathleen R. Whitten, William L. Garbrecht, Gifford P. Marzoni, C. John Parli
  • Cycloalkylamides of (8.beta.)-1-alkyl-6-(substituted) ergolines
    Patent number: 4931447
    Abstract: This invention provides (8.beta.)-N-cycloalkyl-1-alkyl-6-(substituted) ergoline-8-carboxamides useful for blocking 5HT.sub.2 receptors in mammals having an excess of serotonin centrally or peripherally. The invention also provides methods for treating hypertension, migraine, vasospasm, thrombosis, ischemia, depression, anxiety, sleep disorders and appetite disorders with a compound of the invention.
    Type: Grant
    Filed: August 14, 1989
    Date of Patent: June 5, 1990
    Assignee: Eli Lilly and Company
    Inventors: Mark M. Foreman, William L. Garbrecht, Gifford P. Marzoni, Kathleen R. Whitten
  • Alkoxy cycloalkanol esters of dihydrolysergic acid
    Patent number: 4914100
    Abstract: Alkoxycycloalkyl esters of 1-substituted-6-C.sub.1-4 straight chain alkyl (or allyl)ergoline-8.beta.-carboxylic acids, useful as 5HT receptor antagonists.
    Type: Grant
    Filed: April 24, 1989
    Date of Patent: April 3, 1990
    Assignee: Eli Lilly and Company
    Inventors: William L. Garbrecht, Gifford P. Marzoni, Kathleen R. Whitten
  • Cycloalkanol esters of dihydrolysergic acid
    Patent number: 4906639
    Abstract: Cycloalkyl or ketocycloalkyl esters of 1-substituted-6-C.sub.1-4 straight chain alkyl (or allyl)-ergoline-8.beta.-carboxylic acids, useful as 5HT receptor antagonists.
    Type: Grant
    Filed: April 11, 1989
    Date of Patent: March 6, 1990
    Assignee: Eli Lilly and Company
    Inventors: Kathleen R. Whitten, William L. Garbrecht, Gifford P. Marzoni, C. John Parli